AI
Sunday, May 24, 2026 3:02:59 PM
Hello my $AMRN Friends! The UK English Prescribing Data is in for March 2026. This completes Q1 2026 showing 13 consecutive Quarters of acceleration of IPE dispensary capsules.
Key Takeaways
• Vazkepa is on a clear trajectory to become the dominant product in this therapeutic category, having already crossed the 50% share threshold in Q3 2025.
• OMG-3 EE's decline accelerated dramatically in 2025 (~39% year-over-year drop), suggesting the competitive displacement is intensifying rather than plateauing.
• Vazkepa's growth continues a trajectory that could exceed 1.8 million capsules in Q2 having surpassed 1.5 million in Q1. (See Slide #3)
• Regional data could reveal concentration risks or untapped geographies for further Vazkepa growth. London, for example, is the largest Region by population yet falls lowest in Total Capsules. (See Slides 6 & 7).
You can view the complete slide presentation here:
https://drive.google.com/file/d/1xbKxIJEPWL-EZvrZpiCQz7m7a0tQptrn/view?usp=sharing
Key Takeaways
• Vazkepa is on a clear trajectory to become the dominant product in this therapeutic category, having already crossed the 50% share threshold in Q3 2025.
• OMG-3 EE's decline accelerated dramatically in 2025 (~39% year-over-year drop), suggesting the competitive displacement is intensifying rather than plateauing.
• Vazkepa's growth continues a trajectory that could exceed 1.8 million capsules in Q2 having surpassed 1.5 million in Q1. (See Slide #3)
• Regional data could reveal concentration risks or untapped geographies for further Vazkepa growth. London, for example, is the largest Region by population yet falls lowest in Total Capsules. (See Slides 6 & 7).
You can view the complete slide presentation here:
https://drive.google.com/file/d/1xbKxIJEPWL-EZvrZpiCQz7m7a0tQptrn/view?usp=sharing
